Expérimentation préclinique et recherche clinique
Expérimentation préclinique et recherche clinique
Contact
Arronax Nantes > Expérimentation préclinique et recherche clinique > Nos Publications

Nos Publications

    • 18F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma. Salaün PY, Campion L, Ansquer C, Frampas E, Mathieu C, Robin P, Bournaud C, Vuillez JP, Taieb D, Rousseau C, Drui D, Mirallié E, Borson-Chazot F, Goldenberg DM, Chatal JF, Barbet J, Kraeber-Bodéré F. (2014) Eur J Nucl Med Mol Imaging. 41, 1501-10.
    • A Compartmental Model of Mouse Thrombopoiesis and Erythropoiesis to Predict Bone Marrow Toxicity After Internal Irradiation.Sas N, Rousseau J, Nguyen F, Bellec E, Larrsson E, Becavin S, Hindorf C, Abadie J, Chouin N, Barbet J. (2014) J Nucl Med. 55, 1355-1360.
    • Chimeric Antibody c.8B6 to O-Acetyl-GD2 Mediates the Same Efficient Anti-Neuroblastoma Effects as Therapeutic ch14.18 Antibody to GD2 without Antibody Induced Allodynia.Terme M, Dorvillius M, Cochonneau D, Chaumette T, Xiao W, Diccianni MB, Barbet J, Yu AL, Paris F, Sorkin LS, Birklé S. (2014) PLoS One. 9:e87210.

  • Bodet-Milin, C., Ferrer, L., Pallardy, A., Eugène, T., Rauscher, A., Faivre-Chauvet, A., Barbet, J., Kraeber-Bodéré, F. (2013) Radioimmunotherapy of B-Cell Non-Hodgkin’s Lymphoma. Front Oncol. 3, 177.

    Carlier, T., Eugène, T., Bodet-Milin, C., Garin, E., Ansquer, C., Rousseau, C., Ferrer, L., Barbet, J., Schoenahl, F., Kraeber-Bodéré, F. (2013) Assessment of acquisition protocols for routine imaging of Y-90 using PET/CT. EJNMMI Res. 3, 11.

    Chérel, M., Gouard, S., Gaschet, J., Saï-Maurel, C., Bruchertseifer, F., Morgenstern, A., Bourgeois, M., Gestin, J.F., Kraeber-Bodéré, F., Barbet, J., Moreau, P., Davodeau, F. (2013) 213Bi Radioimmunotherapy with an Anti-mCD138 Monoclonal Antibody in a Murine Model of Multiple Myeloma. J. Nucl. Med. 54, 1597-1604.

    Frampas, E., Rousseau, C., Bodet-Milin, C., Barbet, J., Chatal, J.F., Kraeber-Bodéré, F. (2013) Improvement of radioimmunotherapy using pretargeting. Front Oncol. 3, 159.

    Laffon, E., Bardiès, M., Barbet, J., Marthan, R. (2013) Calculating an estimate of tissue integrated activity in 18F-FDG PET imaging using one SUV value. EJNMMI Res. 3, 26.

    Mauxion, T., Barbet, J., Suhard, J.M., Pouget, J.P., Poirot, M., Bardiès, M. (2013) Improved realism of hybrid mouse models may not be sufficient to generate reference dosimetric data. Med Phys. 40, 052501.

    Rousseau, C., Kraeber-Bodéré, F., Barbet, J., Chatal, J.F. (2013) Pretargeted radioimmunotherapy : clinically more efficient than conventional radioimmunotherapy ? Eur J Nucl Med Mol Imaging. 40, 1373-1376.

    Chatal JF, Barbet J, Kraber-Bodéré F, Goldenberg DM. Medullary Thyroid Carcinoma. In : Nuclear Medicine Therapy : Principles and clinical applications. C. Aktolun et S.J. Goldsmith (eds.), Springer Verlag+Business Media, New-York, 2013.

    Barbet, J., Chatal, J.F. Cyclotron-based Radiopharmaceuticals for Nuclear Medicine Therapy. In : Therapeutic Nuclear medicine. Editor : Richard Baum. Springer. In press.

    Kraeber-Bodéré, F., Faivre-Chauvet, F., Bodet-Milin, C., Wegener, W.A., Chatal, J.F., Goldenberg, D.M. Fractionated Radioimmunotherapy of Non-Hodgkin Lymphoma with 90-Y-Labeled Anti-CD22 Antibody, Epratuzumab Tetraxetan. In : Therapeutic Nuclear medicine. Editor : Richard Baum. Springer. In press.

    • Barbet J, Bardiès M, Bourgeois M, Chatal JF, Chérel M, Davodeau F, Faivre-Chauvet A, Gestin JF, Kraeber-Bodéré F. Radiolabeled antibodies for cancer imaging and therapy. Methods Mol Biol. 2012, 907, 681-697.
    • Chatal JF, Kraeber-Bodéré F, Goldenberg DM. Treatment of Metastatic Medullary Thyroid Cancer With Vandetanib : Need to stratify patients on basis of calcitonin doubling time. J Clin Oncol. 2012, 30, 2165.
    • Barbet J, Chatal JF. The best radionuclide for radioimmunotherapy of small tumors : beta- or alpha-emitter ? Eur J Nucl Med Mol Imaging. 2011, 38, 271-273.

  • Barbet J., Chérel M., Chatal J.F. Alpha particles more promising than toxins ? Eur J Nucl Med Mol Imaging. 2010, 37, 849-850.

    Kraeber-Bodéré, F., Salaün, P.Y., Oudoux, A., Goldenberg, D.M., Chatal, J.F., Barbet, J. Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer. Cancer. 2010, 116, 1118-1125.

    C . Koumeir, F. Haddad, V. Metivier, N.Servagent and N. Michel. A new facility for High energy PIXE at the ARRONAX Facility, European Conference On x-ray spectrometry, Figueira da Foz, Coimbra (PORTUGAL) 20-25 June 2010.

  • Ansquer, C., Kraeber-Bodéré, F., Chatal, J.F. Current status and perspectives in peptide receptor radiation therapy. Curr Pharm Des., 2009, 15 : 2453-2462.

    Barbet J, Chatal JF, Kraeber-Bodéré F. Les anticorps radiomarqués pour le traitement des cancers. Med Sci (Paris). 2009, 25, 1039-1045.

    Chatal J.F., Davodeau F., Chérel M., Barbet J. Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors. J Cancer Res Ther, 2009, 5, S36-S40.

    Kraeber-Bodéré, F., Goldenberg, D.M., Chatal, J.F., Barbet, J. Current Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer. Current Oncology, 2009, 16, 3-8.